Clinical bottom line
Rare inherited skeletal ciliopathies represent a heterogeneous group of disorders characterized by skeletal abnormalities alongside multisystem involvement, including renal, hepatic, and retinal manifestations. Current clinical evidence emphasizes the importance of multidisciplinary management tailored to the specific organ systems affected. Diagnosis remains challenging due to phenotypic overlap with other rare multisystem disorders, but advances in genetic testing and clinical decision-support tools are improving case identification. Therapeutic strategies remain largely supportive and symptomatic, with ongoing research into targeted molecular therapies. Clinicians should maintain vigilance for progressive complications and coordinate care across specialties to optimize outcomes.
What the evidence shows
Skeletal ciliopathies are caused by defects in primary cilia, cellular organelles critical for signaling pathways involved in skeletal development and organogenesis (Habbig et al., 2015). These disorders often present with characteristic skeletal dysplasia, including short ribs, polydactyly, and abnormal bone growth, accompanied by variable involvement of kidneys, liver, and eyes. The multisystem nature of these diseases requires comprehensive clinical evaluation.
Yannakoudakis et al. (2013) provide an overview of common skeletal features in rare diseases, highlighting ciliopathies as a key category with distinctive radiographic and clinical hallmarks. Puniya et al. (2025) describe VACTERL-H syndrome, a rare multisystem disorder with skeletal anomalies and additional visceral malformations, underscoring the complexity of differential diagnosis.
Diagnostic challenges are compounded by phenotypic overlap with other inherited multisystem disorders such as hypohidrotic ectodermal dysplasia (Indian Journal of Experimental Biology, 2022). Molecular genetic testing, including next-generation sequencing panels targeting ciliopathy-associated genes, is increasingly utilized to confirm diagnosis.
Faviez et al. (2021) demonstrate the utility of diagnosis support systems leveraging large-scale clinical databases to identify rare ciliopathy cases, which may help shorten diagnostic delay and guide appropriate management.
Renal involvement is a common and serious complication, often manifesting as cystic kidney disease or progressive renal failure. Molinari et al. (2019) highlight the use of patient-derived renal epithelial cells to model kidney disease in inherited ciliopathies, providing a platform for understanding pathophysiology and testing therapeutic agents.
Management remains supportive, focusing on monitoring and treating organ-specific complications. Multidisciplinary care teams including nephrologists, orthopedists, geneticists, and ophthalmologists are essential. Early recognition of complications such as renal insufficiency or hepatic fibrosis can guide timely interventions.
Caveats and uncertainty
The rarity and phenotypic heterogeneity of skeletal ciliopathies limit large-scale clinical trials or standardized treatment protocols. Most evidence derives from case reports, small case series, or translational studies, which may not generalize broadly.
Genotype-phenotype correlations remain incompletely understood, complicating prognostication and individualized therapy. The impact of emerging molecular therapies is still under investigation, and no disease-modifying treatments have yet been validated in clinical trials.
Diagnostic support tools show promise but require further validation in diverse clinical settings to confirm sensitivity and specificity. Additionally, overlapping features with other rare multisystem disorders necessitate cautious interpretation of clinical and genetic findings.
How this may change practice
Clinicians should consider skeletal ciliopathies in patients presenting with characteristic skeletal anomalies plus multisystem involvement, particularly renal and hepatic abnormalities. Early referral for genetic testing and multidisciplinary evaluation can facilitate diagnosis and optimize management.
Integration of clinical decision-support systems into practice may aid in recognizing rare ciliopathies, potentially shortening the diagnostic odyssey. Use of patient-derived cellular models may inform future personalized therapeutic approaches.
Ongoing surveillance for progressive organ dysfunction is critical, and clinicians should coordinate care across specialties to address the full spectrum of disease manifestations. Awareness of current limitations underscores the need for enrollment in registries and clinical studies to advance understanding and treatment.